GLP-1 Receptor Agonists

Introduction to GLP-1 RAs

GLP-1 receptor agonists are recommended to be used with caution in patients with a history of pancreatitis, considering the potential risks and benefits, particularly for cardiovascular benefit in high-risk patients, as suggested by the American College of Cardiology 1
The FDA and European Medicines Agency have not identified a causal link between GLP-1 receptor agonists and either pancreatitis or pancreatic cancer, despite post-marketing case reports suggesting associations 1

When a GLP-1 receptor agonist is strongly indicated, such as for cardiovascular benefit in high-risk patients, consider liraglutide with extreme caution and close monitoring, alongside slower dose titration, lower target doses, and clear patient education about pancreatitis symptoms, as recommended by the American College of Cardiology 1
The American College of Cardiology recommends monitoring blood glucose more closely during the first 4 weeks of therapy, and reducing the dose of sulfonylurea by 50% or basal insulin dose by 20% when starting therapy if A1C is well-controlled at baseline or there's a history of frequent hypoglycemic events 1

The American College of Cardiology recommends starting Dulaglutide at 0.75 mg once weekly, then titrating to 1.5 mg once weekly as tolerated 2
The American College of Cardiology and Mayo Clinic recommend starting Exenatide at 5 μg twice daily, which can be increased to 10 μg twice daily after 1 month, and starting Lixisenatide at 10 μg once daily, increasing to 20 μg once daily after 14 days 3
The FDA-approved dosing protocol for oral semaglutide (Rybelsus) involves a gradual titration schedule:
The initial dose of semaglutide is 0.25 mg once a week for 4 weeks, followed by a titration to 0.5 mg and then 1.0 mg as tolerated, with dose adjustments for renal impairment:

eGFR (mL/min/1.73m²)	Dose Adjustment
≥30	No adjustment
<30	Use with caution

GLP-1 receptor agonists are contraindicated in patients who are pregnant or breastfeeding, as noted by the American College of Cardiology 2
GLP-1 receptor agonists are contraindicated for use in combination with monoamine oxidase inhibitors, and their use with DPP-4 inhibitors is not recommended, as stated by the American Heart Association 5
Patients with a personal or family history of medullary thyroid carcinoma or MEN2 should avoid GLP-1 RAs, and patients with severe hypersensitivity to the drug or active acute pancreatitis should not use GLP-1 RAs, as advised by the National Comprehensive Cancer Network and the American College of Gastroenterology 6
The American College of Cardiology recommends using GLP-1 RAs with caution in patients with a history of pancreatitis, gastroparesis, or diabetic retinopathy (particularly with semaglutide) 1

GLP-1 receptor agonists reduce the risk of major cardiovascular events, with liraglutide reducing the primary composite outcome (MI, stroke, or cardiovascular death) by 13% (absolute rate 13.0% vs 14.9%) 7
Semaglutide shows similar cardiovascular benefits with a 26% reduction in the primary composite outcome (HR 0.74; 95% CI 0.58-0.95) 8
The SUSTAIN-6 study demonstrated a 26% reduction in the primary composite outcome (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) (HR 0.74; 95% CI 0.58-0.95; P<0.001) in patients with diabetes type 2 and CKD treated with semaglutide, as supported by the Kidney International guidelines 8

Most GLP-1 RAs, including dulaglutide and liraglutide, can be used without dose adjustment in reduced renal function, even with eGFR down to 15 ml/min/1.73 m², as stated by the National Kidney Foundation 9
GLP-1 receptor agonists reduce albuminuria and slow eGFR decline, with regular assessment of kidney function (eGFR) crucial for patients with renal impairment 9, 5
No dose adjustment is required for liraglutide for renal impairment down to eGFR 15 ml/min/1.73 m², as stated by the National Kidney Foundation 9, 5
No dose adjustment is required for semaglutide for eGFR ≥30 ml/min/1.73 m², according to the American Diabetes Association 9, 5